Kalaris to present at noble capital markets 2025 emerging growth equity conference

Palo alto, calif., june 02, 2025 (globe newswire) -- kalaris therapeutics, inc. (nasdaq: klrs) (“kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming noble capital markets 2025 emerging growth virtual equity conference.
NE Ratings Summary
NE Quant Ranking